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Abstract Purpose: To compare
dexmedetomidine (DEX) with stan-
dard care (SC, either propofol or
midazolam) for long-term sedation in
terms of maintaining target sedation
and length of intensive care unit
(ICU) stay. Methods: A pilot, phase
III, double-blind multicenter study in
randomized medical and surgical
patients (n = 85) within the first 72 h
of ICU stay with an expected ICU
stay of C48 h and sedation need for
C24 h after randomization. Patients
were assigned to either DEX
(B1.4 lg kg-1 h-1; n = 41) or SC
(n = 44), with daily sedation stops.
Results: Non-inferiority of DEX
versus SC was not confirmed. Target
Richmond agitation–sedation score
(RASS) was reached a median of
64% (DEX) and 63% (SC) of the
sedation time (ns). The length of ICU
stay was similar in DEX and SC.
Patients with RASS target 0–3 (DEX
78%, SC 80%) were at target sedation
74% (DEX) and 64% (SC) of the time
(ns), whereas those with RASS target
-4 or less reached the target 42%
(DEX) and 62% (SC) of the time
(P = .006). Post hoc analyses sug-
gested shorter duration of mechanical
ventilation for DEX (P = 0.025).
Conclusions: This pilot study sug-
gests that in long-term sedation, DEX
is comparable to SC in maintaining
sedation targets of RASS 0 to -3 but
not suitable for deep sedation (RASS
-4 or less). DEX had no effect on
length of ICU stay. Its effects on
other relevant clinical outcomes, such
as duration of mechanical ventilation,
should be tested further.
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Introduction
Sedation is used in the intensive care unit (ICU) to
enhance patient comfort and safety, facilitate mechanical
ventilation and reduce oxygen demands. Side effects may
include prolonged mechanical ventilation and ICU stay
[1–3]. Although sedation protocols and daily sedation
stops may reduce excessive sedation due to drug
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accumulation and shorten ICU stay [1, 2], the manage-
ment of long-term sedation with traditional sedatives
remains problematic.
Dexmedetomidine is a sedative with high affinity for
a2-adrenoreceptors [4]. It sedates via interaction with the
locus ceruleus, and has less effect on arousability and
patient interaction [5, 6]. In post-surgical patients, dex-
medetomidine does not interfere with respiration rate, or
arterial oxygenation and carbon dioxide pressure [7]. The
cardiovascular effects of dexmedetomidine are dose
dependent, and include decreases in heart rate, cardiac
output, and arterial and pulmonary arterial pressures
[8, 9].
Dexmedetomidine has been studied in the ICU mainly
for sedation after surgery up to 24 h [6, 10, 11]. Data from
small uncontrolled studies suggest that dexmedetomidine
may be safe and effective for long-term sedation as well
[12, 13]. In a small uncontrolled series, dexmedetomidine
infused continuously for up to 7 days was an effective
sedative and analgesic-sparing drug [12]. To obtain suf-
ficient sedation for several days, dexmedetomidine doses
had to be increased up to three times the initially sched-
uled doses [13]. Recently, the first randomized, controlled
trial on the use of dexmedetomidine for up to 5 days
found that as compared to lorazepam infusion, sedation
by dexmedetomidine was associated with increased days
alive without delirium or coma in mechanically ventilated
ICU patients [14].
The hierarchical co-primary objectives of this study
were, first, to assess if sedation with dexmedetomidine
(higher doses and/or longer duration than approved) is as
good as standard sedation (with propofol/midazolam and
daily sedation stops) in maintaining target sedation level
in long-stay ICU patients, and second, to compare the
effects of dexmedetomidine and standard sedation on
length of ICU stay.
Materials and methods
For details, see electronic supplementary material (ESM).
This multicenter, prospective, randomized, double-blind,
double-dummy, active comparator study was approved
by the Finnish national research ethics committee and by
the Ethics Committee of the Canton of Bern, Switzer-
land. Written informed consent was obtained either from
the patient’s family (3 centers) or from the family and an
independent physician (1 center). An independent data
safety monitoring board had full access to the data. The
study treatment was started within 72 h of ICU admis-
sion. Patients were randomized to either continue their
current standard care (midazolam or propofol; SC) or to
switch to dexmedetomidine (DEX). Randomization was
stratified for study center, current sedative, sedation tar-
get (Richmond Agitation–Sedation Scale [15]; RASS)
0 to -3 vs. RASS -4, and admission type (medical
vs. postoperative/trauma). Study treatments were titrated
to individual sedation targets. Pain was treated with
fentanyl boluses, as clinically indicated. Rescue medi-
cation (first-line rescue propofol for patients receiving
midazolam, midazolam for those receiving propofol
before randomization; further rescue medication decided
by clinician in charge) could be given if needed to
achieve the target depth of sedation. Need for sedation
was assessed at a daily sedation stop (used routinely
in all centers before the study), conducted at the same
time each day. The first sedation stop was 12–36 h
after randomization, depending on the time of randomi-
zation. The study treatment lasted a maximum of 14 days
from randomization and the follow-up for 45 days
(Fig. 1).
The main inclusion criteria were age C18 years,
mechanical ventilation, need for sedation for C24 h after
randomization and an expected ICU stay C48 h. The
exclusion criteria were acute severe neurological disorder,
mean arterial pressure \55 mmHg despite volume and
vasopressors, heart rate\50 beats min-1; AV-conduction
block II–III (unless pacemaker installed), hepatic
Sequential Organ Failure Assessment (SOFA) score
[16] [2, bilirubin [101 lmol L-1, lactation or positive
pregnancy test, muscle relaxation, loss of hearing or
vision, any other condition interfering with RASS
assessment, use of a2-agonists or antagonists at the time
of randomization.
Dexmedetomidine and dexmedetomidine dummy
(0.9% NaCl), propofol 2% and propofol dummy (0.9%
NaCl) and midazolam (0.1%) and midazolam dummy
(0.9% NaCl) were prepared by personnel not involved in
the study or the patient’s care; infusion systems for pro-
pofol and its dummy were nontransparent. In order to
maintain the target RASS, dexmedetomidine was infused
without a loading dose at 0.8 lg kg-1 h-1 for 1 h and
then adjusted stepwise at 0.25, 0.5, 0.8, 1.1, and
1.4 lg kg-1 h-1; propofol was infused at 2.4 mg kg-1h-1
for 1 h and then adjusted stepwise at 0.8, 1.6, 2.4, 3.2, and
4.0 mg kg-1 h-1. Depending on standard care at time of
randomization, midazolam was given either as intrave-
nous boluses (1–2 mg), starting at 3 boluses per hour for
1 h, and thereafter 1–4 boluses per hour, and if not suf-
ficient as continuous infusion of 0.2 mg kg-1 h-1, or as a
continuous infusion at 0.12 mg kg-1 h-1 for 1 h, fol-
lowed by adjustments at 0.04, 0.08, 0.12, 0.16, and
0.20 mg kg-1 h-1. The initial dose could be reduced, if
considered necessary by the treating clinician.
Primary efficacy variables Depth of sedation was
assessed using the RASS (routinely used in all centers
before study), and the target RASS was determined before
starting study treatment and at the daily sedation stops.
RASS was assessed every 2 h during the treatment.
Length of ICU stay was measured from ICU admission
and from randomization to medically fit for discharge.
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Secondary efficacy variables included nurses’ assess-
ment of arousal, cooperation, and ability to communicate
pain with visual analogue scales (VAS), duration of
mechanical ventilation, weaning time, ventilator-free days
in the ICU, length of hospital stay (actual and until
medically fit for discharge), functional recovery during
hospitalization [17], and need for rescue medication. For
safety variables and adverse events (AEs), see ESM.
Delirium was assessed daily by trained study personnel
[18].
Statistical methods
The hierarchical co-primary objectives were, first, to
evaluate the non-inferiority of DEX versus SC in main-
taining target RASS, and second, to compare effect of
DEX versus SC on length of ICU stay. Maintenance of
target sedation (proportion of sedation time within RASS
target, without rescue medication) was analyzed using
analysis of co-variance (ANCOVA; main effects treat-
ment, stratification factors used in randomization;
covariate time from admission to randomization). Non-
inferiority of DEX versus SC was defined (using per-
protocol data set to avoid bias towards non-inferiority,
and one-sided 97.5% confidence interval; CI) as \10%
difference between the treatments (lower CI of the esti-
mated DEX/SC [0.90).
Intention-to-treat data were used for all other efficacy
variables. The length of ICU stay to medically fit for
discharge was analyzed with Kaplan–Meier method and
Cox’s proportional-hazards regression model (including
stratification factors and time from admission to ran-
domization). Duration of mechanical ventilation and time
to hospital discharge were analyzed using Cox’s propor-
tional-hazards regression model and ventilator-free days
in ICU using generalized linear model (effect for treat-
ment and length of ICU stay as offset variables) with post
hoc adjustments for baseline stratification factors, and the
VAS results using ANCOVA (effect for treatment and
baseline as covariate).
Imputation rules for length of ICU stay and duration of
mechanical ventilation were modified post hoc to include
all scenarios for missing data (see ESM). The results in the
main text are given using the modified imputation rules.
The plan was to recruit 90 patients as a separate pilot
study and to continue recruiting up to 900 patients (450
each in DEX and SC). After 85 pilot patients, the study
was discontinued and analyzed for subsequent design of
two pivotal studies.
Categorical data were analyzed using Fisher’s exact
test or the Chi square test. SAS statistics software was
used (SAS version 9.1, SAS Institute Inc., Cary, NC,
USA).
Results
Ninety-five patients were screened and 85 were random-
ized (intention-to-treat patients) to receive dexme-
detomidine (DEX; n = 41) or to continue their previous
standard care (SC; n = 44) (Table 1; Fig. 2). Seventy-
nine patients (93%; 38 DEX; 41 SC) were included in the
per-protocol analysis (Fig. 2). The occurrence rate and
Dex+midazolam dummy
0 h < 72 h from
ICU admission
2-14 d
from R
48 h
from last
sedation
stop
< 36 h from
starting sedation
Double blind-double dummy design
- expected length of stay > 48 hours and need for sedation > 24 hours from randomisation
- drugs titrated to target sedation range using Richmond Agitation-Sedation Scale (RASS)
- need for continued sedation assessed at daily sedation stop
- primary comparison: ”usual care” (combined midazolam + propofol groups) vs. combined dex groups
- hospital discharge recorded
31 d
from R
45 d
from R
R = Randomisation
Dex = Dexmedetomidine
Screening
& consent
Propofol+dex dummy
Patients on
propofol
48-h follow-
up
R
R
Pa
tie
nts
on
m
ida
zo
lam
Dex+propofol dummy
Follow-up by
telephone
contacts
Patients
admitted to ICU
and sedated
using propofol
or midazolam
Midazolam+dex dummy
Fig. 1 Schematic diagram of
study protocol
284
severity of organ failures at baseline were comparable
between the treatment groups (Table 1). Duration and
dose of study drugs is given in Table 2. Use of fentanyl
was similar in DEX and SC (Table 2). There was no
significant difference between treatments in need for
rescue medication.
Non-inferiority of DEX versus SC was not confirmed.
DEX and SC resulted in similar proportions of time at
target sedation without rescue medication (DEX 64 vs.
SC 63%; Table 3). The estimated ratio between DEX/SC
in time at target sedation was 0.97 (95% CI 0.79–1.15).
The lower limit of the 95% CI did not reach the limit of
Table 1 Demographics, the presence of infection at ICU admission and occurrence rate and severity of organ failures at baseline
Variable Dexmedetomidine N = 41 Midazolam/propofol N = 44 P valuea
Age (years) Median 64, range 18–83 Median 68, range 18–83
Female/male (n) 9/32 6/38
Medical patients 21 (51%) 24 (55%)
Infection at ICU admission 23 (56%) 20 (45%) 0.388
Respiratory system SOFA [1 41 (100%) 44 (100%) 1.000
SOFA 3 or 4 36 (87.8%) 38 (86.4%)
Coagulation SOFA [1 15 (36.6%) 15 (34.1%) 0.174
SOFA 0 or 1 26 (63.4%) 29 (65.9%)
Liver SOFA [1 5 (12.2%) 3 (6.8%) 0.206
SOFA 0 or 1 36 (87.8%) 41 (93.2%)
Cardiovascular system SOFA [1 28 (68.3%) 31 (70.5%) 0.182
SOFA 0 or 1 13 (31.7%) 13 (29.5%)
Central nervous systemb SOFA [1 2 (4.9%) 2 (4.5%) 0.384
SOFA 0 or 1 38 (92.7%) 40 (90.9%)
Kidney SOFA [1 13 (31.7%) 12 (27.3%) 0.170
SOFA 0 or 1 28 (68.3%) 32 (72.7%)
A sequential organ failure assessment score (SOFA) [1 was con-
sidered as organ failure. Respiratory system SOFA 3 and 4 indicate
PaO2/FiO2 \200 and \100, respectively, during mechanical
ventilation
a Fisher’s exact test
b Missing central nervous system SOFA scores at baseline, dex-
medetomidine n = 1, midazolam/propofol n = 2
Screened (n=95 )
Randomized  
SC (n=44)
propofol n=28, midazolam n=16)
Excluded at screening 
(n=10)
Completed study treatment 
SC (n=37 )
Reasons for discontinuation:
lack of efficacy ( n=1)
adverse event ( n=5)
protocol violation ( n=1)
Discharged from hospital
SC (n=25 )
Died in hospital SC (n=7)
of these in ICU**:  (n=2)
In hospital at 45-day follow-up
DEX (n=12 ) 
**refers to the initial ICU admission
per-protocol population:
DEX (n=38 of 41), 
SC (n=41 of 44; propofol n=27, midazolam n=14)
Reasons for exclusions:
short exposure (<12hrs) (DEX n=1, SC n=1)
missing RASS-assessments (DEX n=2, SC n=1) 
both short exposure and missing RASS assessments (DEX n=0, SC n=1)
Randomized 
DEX (n=41)  
Completed study treatment 
DEX (n=31 ) 
Reasons for discontinuation:
lack of efficacy (n=6)
adverse event (n=3)
discharge to another hospital (n=1)
Discharged from hospital
DEX (n=19 ) 
In hospital at 45-day follow-up
SC (n=12 )
Died in hospital DEX (n=10)
of these in ICU**: (n=2)
Intention-to-treat population
(n=85)
Fig. 2 Randomization,
completion of study treatment,
reasons for discontinuation of
study treatment, and patient
outcomes in intention-to-treat
population; inclusions into per-
protocol population and reasons
for exclusions. Note: one
patient in each study arm was
lost to follow-up after day 31;
both were still hospitalized after
discharge to another hospital,
and were considered as being in
hospital at 45-day follow-up
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non-inferiority of DEX versus SC (at least 0.90). The
lengths of stay from admission and randomization to
medically fit for discharge from the ICU were similar in
both treatment groups (Table 3; Fig. 3).
Target sedation at baseline influenced the time spent at
RASS without rescue medication (P = 0.057 for treat-
ment9target RASS interaction). Of those with target
RASS -4, DEX patients (n = 8) spent 42% (median;
range 4–64%) of the time at target RASS, and SC patients
(n = 8) 62% (0–85). DEX patients with baseline target
RASS of 0 to -3 (n = 30) were at target RASS 74% of
the time (median; range 0–99%) and SC patients
(n = 33) 64% (9–100%).
Sedation stops (Table 2) were performed on 71% of
days in the DEX group and 70% in the SC group. The
most common reason a sedation stop was not performed
was clinical contraindication, e.g., severe gas exchange
disturbance or high risk of hemodynamic instability
(DEX 21.4%, SC 20.9% of sedation days). The most
common reasons to restart sedation after a sedation stop
were poor tolerance of the endotracheal tube or
mechanical ventilation (DEX 18 events, SC 30 events),
agitation or anxiety (DEX 19 events, SC 31 events), and
cardiovascular instability (DEX 6 events, SC 11 events).
The median duration of mechanical ventilation was
77.2 h (17.5–338.8 h) in the DEX group and 110.6 h
(20.1–675.0 h) in the SC group (P = 0.109; Fig. 3).
When adjusted post hoc for study center, sedative agent
before randomization, and target sedation level, the
duration of mechanical ventilation was shorter with DEX
(P = 0.025). In patients with light to moderate sedation
(RASS 0 to -3), the median duration of mechanical
ventilation in the DEX group was 70.2 h (17.5–225.4 h)
versus median 93.7 h (20.1–675.0 h) in the SC group
(P = 0.135, after post hoc adjustment P = 0.027). There
were no significant differences between the groups in
duration of weaning, number of ventilator-free days, or
time to discharge from the hospital (for details, see ESM).
Ten DEX patients (24.4%) and 7 SC patients (15.9%)
died between randomization and day 45 follow-up.
The VAS score of nurses’ assessment of patient
communication (lower scores indicate better response)
Table 2 Duration (excluding sedation stops) and dose of study drugs, use of
fentanyl, and duration of sedation stops; median (range)
Dexmedetomidine Standard care
Duration of study drug
administration (h)
40 (3–198) Midazolam boluses
24 (8–83)
midazolam infusion
27 (4–105)
propofol infusion
61 (15–256)
Dose of study drug
(lg kg-1 h-1)
0.8 (0.3–1.4) Midazolam boluses
37 (27–76)
midazolam infusion
87 (44–160)
propofol infusion
2067 (845–3659)
Cumulative dose
of fentanyl (mg)
1.5 (0.1–20) 1.6 (0.1–9)
Duration of sedation
stop (h)
2.3 (0–29.0) 1.1 (0–49.1)
midazolam 10.3 (0–49.1)
propofol 0.7 (0–28.1)
Table 3 Percentage of time at target sedation without rescue medication; median (range) and length of ICU stay to medically fit for
discharge; days, median (range)
Dexmedetomidine
(N = 38/41)
Standard care
(midazolam or propofol)
(N = 41/44)
P valuea Hazards
ratioa
95% CIa
Time at target sedation (%) 64 (0–99) 63 (0–100)
Midazolam 63 (0–100)
Propofol 63 (9–100)
Estimated ratio DEX/SCb 0.97 0.79–1.15
Length of ICU stay to medically fit for discharge (days)
From admission 6.6 (2.2–20.7) 6.8 (2.6–30.8)
Midazolam 6.9 (3.3–30.8)
Propofol 6.8 (2.6–28.2)
0.275 0.766 0.476–1.235
From randomization 5.5 (1.7–19.5) 5.7 (1.7–29.0)
Midazolam 5.8 (1.8–29.0)
Propofol 5.2 (1.7–27.1)
0.411 0.821 0.512–1.315
For medical patients 5.0 (1.7 –19.5) 4.9 (1.8 –29.0)
Midazolam 6.0 (1.8–29.0)
Propofol 4.7 (1.8–27.1)
0.016 0.427 0.213–0.854
For postoperative and/or trauma patients 5.7 (2.0 –16.7) 5.9 (1.7–16.8)
Midazolam 5.8 (2.9–16.8)
Propofol 6.7 (1.7–11.5)
0.062 2.091 0.964–4.533
Patient numbers (N) refer to per-protocol/intention-to-treat popu-
lation, respectively
a Cox proportional-hazard model for length of stays
b Lower 95% confidence limit of the estimated DEX/SC ratio
[0.90 indicates that dexmedetomidine (DEX) is non-inferior to
standard care with propofol or midazolam (SC)
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demonstrated that DEX patients were more arousable,
more cooperative, and better able to communicate their
pain than SC patients [mean (SD) sum of VAS scores
DEX 30.6 (21.0) vs. SC 47.5 (27.7); P \ 0.001 for the
sum and each VAS].
Delirium was more common in the DEX group (43.9
vs. 25.0% in SC; P = 0.035) when analyzed as the
combined endpoint of CAM-ICU and adverse events
(AEs) of delirium and confusion. However, more CAM-
ICU assessments were performed in the DEX group (106
DEX vs. 84 SC assessments), and the proportion of
positive CAM-ICU results was comparable (DEX 17.0 vs.
SC 17.9%, n.s.). During the follow-up to ICU discharge,
no significant difference was observed in the occurrence
rate of positive RASS scores (DEX 26 vs. SC 32%).
Serious adverse events (SAE) were equally common:
41 DEX patients (including 3 patients with bradycardia,
1 cardiac arrest 5 days after end of treatment) and 47 SC
patients had SAEs. There were no differences between
groups in the incidence of any SAE (see ESM). All DEX
patients and 95.5% of SC patients had AEs (a total of
296 in DEX and 275 in SC). At day 2, a cardiovascular
SOFA score [1 was more common in DEX (77.5 vs.
56.1% in SC; P = 0.024), indicating more frequent use
of vasopressors/inotropes in the first 24 h of study
treatment.
Discussion
This randomized, controlled, double-blind, double-
dummy trial of dexmedetomidine for long-term sedation
extended the duration of dexmedetomidine use and
compared its efficacy in maintaining target sedation levels
with standard care in a broad spectrum of long-stay
intensive care patients. The standard sedation was opti-
mized by using daily sedation stops and frequent sedation
scoring. As a pilot study, this study was not powered for
its co-primary outcomes (non-inferiority in maintaining
target sedation levels and length of ICU stay). Based on
its results, two pivotal studies have been designed and are
currently running (http://www.ClinicalTrials.gov, identi-
fiers NCT00481312, NCT00479661). Despite its pilot
Fig. 3 Probability of remaining on mechanical ventilation and staying in the intensive care unit (Kaplan–Meier curves)
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character, this study provides relevant information on the
safety, efficacy, and characteristics of dexmedetomidine
in long-term sedation. The only previous randomized
controlled trial on dexmedetomidine for long-term seda-
tion (up to 5 days) in ICU patients used lorazepam
infusion without sedation stops as comparator [14]. In
contrast, patients in our study continued their previous
care, including sedation stops, as comparator.
Although the non-inferiority of dexmedetomidine
versus standard care was not confirmed, the proportion
of time at target sedation without rescue medication and
the need for rescue medication were similar in the
treatment groups. Dexmedetomidine was more applica-
ble for moderate sedation than deep sedation despite the
use of a higher maximum dose of dexmedetomidine
(1.4 lg kg-1 h-1) than in most previous studies [10–12].
A need for additional sedatives has been reported with
dexmedetomidine at doses of up to 2.5 lg kg-1 h-1
[13]. Dexmedetomidine was associated with less coma
(defined as RASS -4 to -5) and markedly increased
fentanyl needs in patients with RASS target -3 or
deeper [14]. When viewed together with its short-term
use [6, 10, 11] and any long-term use [12–14], our
results suggest that dexmedetomidine should be further
assessed for mild to moderate sedation rather than as
sole sedative for deep sedation.
Use of sedation protocols with daily sedation stops and
sedation scores has been able to reduce the duration of
mechanical ventilation and intensive care [1, 2]. Pand-
haripande [14] observed a tendency toward more
ventilator-free days with dexmedetomidine. Since no
sedation stops were used, the more frequent oversedation
with lorazepam may have contributed. In the present
study, sedation stops and score-targeted sedation were
used in both treatment groups, and 2/3 of patients in SC
received propofol, a short-acting agent. Still, the duration
of mechanical ventilation tended to be shorter in patients
receiving dexmedetomidine. Since the reduction of
duration of mechanical ventilation in the present study
was significant only after post hoc baseline stratification
adjustments, this finding must be regarded as hypothesis-
generating. Furthermore, shorter mechanical ventilation
did not translate to reduced duration of ICU stay. The
relevance of this finding remains speculative; conceiv-
ably, shorter mechanical ventilation may, e.g., reduce
nosocomial infections and need for tracheostomy. The
medication costs of sedation with DEX are likely to be
higher than those of SC. These must be balanced with the
potential impact on other components of intensive care
and hospitalization. The overall costs of sedation with
dexmedetomidine need to be evaluated.
The similar length of ICU stay despite the tendency
toward shorter mechanical ventilation in the DEX group
deserves consideration. Delirium, agitation, or anxiety
could prolong the length of ICU stay in already extubated
patients. This is unlikely, since the occurrence rate of
agitation (positive RASS) was similar in the groups after
stopping mechanical ventilation.
Delirium, confusional state, and positive CAM-ICU
(but not the proportion of positive CAM-ICU of those
assessed) were more frequent in DEX, whereas sedation
needed to be restarted after a sedation stop due to agita-
tion or anxiety more frequently in SC. A retrospective
analysis suggested increased pain and agitation when
dexmedetomidine was begun to reduce standard sedation
[19]. On the other hand, dexmedetomidine has been
proposed to reduce agitation [20] and delirium [21], and
alphareceptor agonists have been used to treat delirium
[22].
Pandharipande [14] used a composite primary end-
point of delirium and coma-free days to compare
dexmedetomidine with lorazepam infusion in 106 ven-
tilated patients. Dexmedetomidine resulted in more days
alive without delirium and coma, and more time with
actual RASS score within one point of target. Since
coma but not delirium was reduced, it is conceivable
that lorazepam infusion resulting in inadvertently deep
sedation may have contributed. Since RASS was asses-
sed twice daily without formal sedation stops, and the
comparator was long-acting [14], their results in
achieving target sedation cannot be directly compared
with ours. Despite differences in study design, the
findings of these two double-blind, randomized, con-
trolled trials support the concept that dexmedetomidine
can provide adequate long-term sedation. At least in
moderate sedation, dexmedetomidine may reduce over-
sedation as compared to either benzodiazepines or
propofol (standard care).
Difficulties in communication and pain assessment
may contribute to oversedation and suboptimal analgesia.
Similar to our results in healthy subjects [5], DEX
patients were more arousable, more cooperative, and
could better communicate pain than patients receiving
standard care. Whether this improves patients’ perception
of sedation is controversial. Both positive perceptions [6]
and increased discomfort and sleeping difficulties as
compared to propofol at similar patient-rated awareness
[11] have been reported.
Dexmedetomidine was well tolerated hemodynami-
cally. Nevertheless, increased cardiovascular SOFA score
was more common during the first day in DEX. Dex-
medetomidine resulted in concentration-dependent
decreases in heart rate, cardiac output, and cerebral blood
flow in healthy subjects [8, 9, 23] and in lower heart rate
but similar blood pressure compared to propofol after
cardiac surgery [11]. We observed no signs of cardio-
vascular instability and/or rebound after cessation of
sedation.
As a pilot study, the sample size is a main limitation.
The standard care comparator included the option of
either propofol or midazolam instead of one comparator.
Accordingly, the standard care consisted of two
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subgroups receiving pharmacologically very different
agents. Although this is a limitation, such standard care
group represents a broad range of patients and clinical
practice, and may provide a better estimate of the
potential effects of dexmedetomidine in clinical routine.
A further potential limitation is that opioids were
administered on clinical grounds, and despite similar
patterns in DEX and SC, differences in sedation may have
been masked, a problem common with all sedation trials.
In conclusion, dexmedetomidine appears safe and
comparable to current sedation practice for long-term
sedation, but not suitable as the sole agent for deep
sedation (RASS -4 or less). Dexmedetomidine enhances
the patient’s ability to communicate. Large randomized
clinical trials to test its effects on relevant clinical out-
comes, such as mechanical ventilation, are underway.
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